Details for Patent: 6,395,754

Title:	Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNF.alpha. levels
Abstract:	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
Inventor(s):	Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee:	Celgene Corporation, et al. (Warren, NJ)
Filing Date:	Feb 22, 2000
Application Number:	09/445,002
Claims:	1. A 2,6-dioxopiperidine selected from the group consisting of (a) a compound of the formula: ##STR6## in which: one of X and Y is C.dbd.O and the other of X and Y is C.dbd.O or CH.sub.2 ; R.sup.6 is hydrogen, alkyl of 1 to 8 carbon atoms, benzyl, chloro, or fluoro; R.sup.7 is m-phenylene, p-phenylene or --(C.sub.n H.sub.2n)-- in which n has a value of 0 to 4; each of R.sup.8 and R.sup.9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R.sup.8 and R.sup.9 taken together are tetramethylene, pentamethylene, hexamethylene, or --CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 -- in which X.sup.1 is --O--, --S-- or --NH--; and, R.sup.10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and, (b) the acid addition salts of said compounds which contain a nitrogen atom capable of being protonated. 2. A compound according to claim 1 wherein R.sup.6 is hydrogen. 3. A compound according to claim 2 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4. 4. A compound according to claim 1 wherein R.sup.6 is alkyl of 1 to 8 carbon atoms. 5. A compound according to claim 1 wherein R.sup.6 is methyl. 6. A compound according to claim 5 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4. 7. A compound according to claim 1 wherein R.sup.6 is ethyl. 8. A compound according to claim 7 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4. 9. A compound according to claim 1 wherein R.sup.6 is propyl. 10. A compound according to claim 9 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4. 11. A pharmaceutical composition comprising a quantity of a compound according to claim 1 sufficient upon administration in a single or multiple dose regimen to reduce levels of TNF.alpha. in a mammal in combination with a carrier. 12. The method of reducing undesirable levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound according to claim 1.